Feature | January 21, 2015

Real-World Data Show Consistent Safety Performance of Once-Daily Rivaroxaban

Results indicate few cases of major bleeding and only in older patient

rivaroxaban, Xarelto, safety performance, Janssen, NVAF

January 21, 2015 — A new post-marketing study evaluating the safety of once-daily rivaroxaban (Xarelto) shows, in patients with non-valvular atrial fibrillation (NVAF), rates and patterns of major bleeding in routine clinical practice are generally consistent with those observed in Phase 3 clinical trials used to approve the medicine for this indication. These 15-month results, published in Clinical Cardiology, represent initial findings from an ongoing, five-year observational study of patients using rivaroxaban daily over the course of their lives.  

“These findings reaffirm the safety profile of rivaroxaban,” said W. Frank Peacock (co-author of the manuscript), M.D., FACEP, associate chair and research director, emergency medicine, Baylor College of Medicine. “We anticipate future findings from this five-year observational study will continue to provide real-world information about the use of Xarelto in routine clinical practice.”

Researchers analyzed data from Jan. 1, 2013, to March 31, 2014, using U.S. Department of Defense (DoD) integrated electronic healthcare records via a collaboration with Health ResearchTx LLC (HRTX) to evaluate major bleeding rates in NVAF patients treated with rivaroxaban in the real-world clinical setting. Of the 27,467 patients receiving rivaroxaban, an incidence of major bleeding was observed at 2.86 per 100 person-years, which was generally consistent with rates reported in the ROCKET-AF clinical trial. Additionally, patients who experienced major bleeding were older (with a mean age of 78) and fatal outcomes were rare.

Janssen Pharmaceuticals Inc. designed the study in conjunction with DoD and HRTX and in agreement with the U.S. Food and Drug Administration (FDA) to proactively ascertain, analyze and report potential side effects with rivaroxaban use;  these included major bleeding events, associated risk factors and bleeding-related clinical outcomes in NVAF patients receiving rivaroxaban. Major bleeding cases for this study were ascertained using a validated Cunningham (2011) algorithm, which was generally consistent with but not identical to the definition of major bleeding used in clinical studies, because it relied on retrospectively identified electronic medical records. While the results are not intended for any direct comparison, these data show rates and patterns of major bleeding were generally consistent with those reported in the previous large randomized FDA registration trial of rivaroxaban.

For more information: www.xarelto-us.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init